
Pharvaris B.V. (PHVS) Stock Forecast & Price Target
Pharvaris B.V. (PHVS) Analyst Ratings
Bulls say
Pharvaris NV's positive outlook is driven by an increased global peak sales estimate for its drug deucrictibant, now projected to reach $1.65 billion by 2037. The clinical data showcases compelling patient outcomes, with 100% of participants achieving “well-controlled HAE” status and reporting significant improvements in health-related quality of life. Additionally, the favorable safety and efficacy profile, highlighted by robust single-dose durability and a significant market gap due to the absence of approved therapies, positions deucrictibant as a strong contender for capturing substantial market share if approved.
Bears say
Pharvaris NV faces significant challenges due to insufficient de-risking of bradykinin B2 receptor antagonism in chronic prophylaxis, which raises concerns about the efficacy and safety of its lead candidate, deucrictibant. The competitive landscape for hereditary angioedema (HAE) treatments is already crowded, with established therapies commanding market dominance, which could hinder Pharvaris's ability to gain traction. Additionally, the impending approval of multiple subcutaneous therapies in development may further dilute the potential market share for deucrictibant, severely impacting its commercial viability.
This aggregate rating is based on analysts' research of Pharvaris B.V. and is not a guaranteed prediction by Public.com or investment advice.
Pharvaris B.V. (PHVS) Analyst Forecast & Price Prediction
Start investing in Pharvaris B.V. (PHVS)
Order type
Buy in
Order amount
Est. shares
0 shares